Cargando…

Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS

BACKGROUND: We tested the hypothesis that moxifloxacin monotherapy is equally effective and safe as a betalactam antibiotic based combination therapy in patients with acute respiratory distress syndrome (ARDS) evoked by severe community acquired pneumonia (CAP). METHODS: In a retrospective chart rev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rahmel, Tim, Asmussen, Sven, Karlik, Jan, Steinmann, Jörg, Adamzik, Michael, Peters, Jürgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471686/ https://www.ncbi.nlm.nih.gov/pubmed/28615012 http://dx.doi.org/10.1186/s12871-017-0376-5

Ejemplares similares

The aquaporin 5 -1364A/C promoter polymorphism impacts on resolution of acute kidney injury in pneumonia evoked ARDS
por: Rahmel, Tim, et al.
Publicado: (2018)

Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia
por: Tang, Hung-Jen, et al.
Publicado: (2020)

A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)
por: Ferrara, Anna M
Publicado: (2007)

Efficacy and safety of sequential IV/PO moxifloxacin for the treatment of severe community-acquired pneumonia
por: Lode, H, et al.
Publicado: (2002)

Moxifloxacin Monotherapy in Left-Sided Staphylococcus aureus Endocarditis
por: Colkesen, Yucel
Publicado: (2021)

Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study
por: Ramirez, Julio, et al.
Publicado: (2021)

Increased circulating microRNA-122 is associated with mortality and acute liver injury in the acute respiratory distress syndrome
por: Rahmel, Tim, et al.
Publicado: (2018)

Increased circulating microRNA-122 is a biomarker for discrimination and risk stratification in patients defined by sepsis-3 criteria
por: Rahmel, Tim, et al.
Publicado: (2018)

Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI)
por: Kuzman, Ilija, et al.
Publicado: (2014)

Decreased protein binding of moxifloxacin in patients with sepsis?
por: Dorn, Christoph, et al.
Publicado: (2017)

LPS-Induced Endotoxemia Evokes Epigenetic Alterations in Mitochondrial DNA That Impacts Inflammatory Response
por: Koos, Björn, et al.
Publicado: (2020)

Severe community acquired pneumonia and ARDS: prognostic factors in infants
por: Chidini, G, et al.
Publicado: (2003)

Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis
por: Zhao, Mingye, et al.
Publicado: (2022)

Major Adverse Kidney Events Are Associated with the Aquaporin 5 -1364A/C Promoter Polymorphism in Sepsis: A Prospective Validation Study
por: Bergmann, Lars, et al.
Publicado: (2020)

Serum metabolite profiles as potential biochemical markers in young adults with community-acquired pneumonia cured by moxifloxacin therapy
por: Zhou, Bo, et al.
Publicado: (2020)

Data in Brief of: Clinical benefits of moxifloxacin as initial treatment of community-acquired pneumonia: Data from meta-analyses
por: Du, Xiwen, et al.
Publicado: (2021)

A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP)
por: Horcajada, Juan P, et al.
Publicado: (2019)

Moxifloxacin modulates inflammation during murine pneumonia
por: Beisswenger, Christoph, et al.
Publicado: (2014)

Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection
por: Lodise, Thomas P., et al.
Publicado: (2021)

Long-term mortality and outcome in hospital survivors of septic shock, sepsis, and severe infections: The importance of aftercare
por: Rahmel, Tim, et al.
Publicado: (2020)

2232. A Global Phase 3 Study of Delafloxacin (DLX) Compared with Moxifloxacin (MOX) in Patients with Community-acquired Bacterial Pneumonia (CABP)
por: Salata, Robert, et al.
Publicado: (2019)

Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial
por: McCurdy, Sandra, et al.
Publicado: (2020)

An increased alveolar CD4 + CD25 + Foxp3 + T-regulatory cell ratio in acute respiratory distress syndrome is associated with increased 30-day mortality
por: Adamzik, Michael, et al.
Publicado: (2013)

Response to comment on human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis
por: Koos, Björn, et al.
Publicado: (2023)

2419. Standard vs. Alternative Therapy for Stenotrophomonas maltophilia Infections: Focus on Trimethoprim–Sulfamethoxazole, Minocycline, and Moxifloxacin Monotherapy
por: Badwal, Jasmin, et al.
Publicado: (2018)

DNA methylation of a NF-κB binding site in the aquaporin 5 promoter impacts on mortality in sepsis
por: Rump, Katharina, et al.
Publicado: (2019)

Evaluation of inhaled salbutamol effectiveness under supportive use of electrical impedance tomography in ventilated ICU patients: study protocol for a randomised controlled clinical trial
por: Rahmel, Tim, et al.
Publicado: (2019)

Epileptic Seizure after Use of Moxifloxacin in Man with Legionella longbeachae Pneumonia
por: Wang, Jin-Yong, et al.
Publicado: (2020)

Effect of therapeutic suggestions during general anaesthesia on postoperative pain and opioid use: multicentre randomised controlled trial
por: Nowak, Hartmuth, et al.
Publicado: (2020)

Moxifloxacin-warfarin interaction
por: Ji, Yan, et al.
Publicado: (2012)

Mitochondrial dysfunction in sepsis is associated with diminished intramitochondrial TFAM despite its increased cellular expression
por: Rahmel, Tim, et al.
Publicado: (2020)

COVID-19 pneumonia: ARDS or not?
por: Gattinoni, Luciano, et al.
Publicado: (2020)

684. Cardiac Safety in Adults with Community-Acquired Bacterial Pneumonia (CABP) Treated with Lefamulin (LEF) or Moxifloxacin (MOX): Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Darpo, Borje, et al.
Publicado: (2019)

Prognostic value of severity indicators of nursing-home-acquired pneumonia versus community-acquired pneumonia in elderly patients
por: Ugajin, Motoi, et al.
Publicado: (2014)

Hypoxia Inducible Factor-2 Alpha and Prolinhydroxylase 2 Polymorphisms in Patients with Acute Respiratory Distress Syndrome (ARDS)
por: Dötsch, Annika, et al.
Publicado: (2017)

699. Hepatobiliary Safety in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Lewis, James H, et al.
Publicado: (2019)

2197. Ceftriaxone Monotherapy vs. Ceftriaxone Plus Azithromycin for the Treatment of Community-Acquired Pneumonia in Hospitalized, Non-ICU Patients
por: Murter, Forrest, et al.
Publicado: (2019)

Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia
por: Tanaseanu, Cristina, et al.
Publicado: (2009)

2590. Efficacy of Doxycycline Versus Azithromycin in Community Acquired Pneumonia
por: Mei, Julie, et al.
Publicado: (2023)

Update on the Cardiac Safety of Moxifloxacin
por: Haverkamp, Wilhelm, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_9d0j70ndda433tjb24996g6ml7